Key Insights

Highlights

Treatment Research

1 treatments under study, led by Human Cord Bloodderived Mononuclear Cells Hcbmncs

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05999656Not ApplicableUnknownPrimary

Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot

Showing all 1 trials

Research Network

Common Treatments

  • Human Cord Bloodderived Mononuclear Cells Hcbmncs1

Active Sponsors

  • Shandong Qilu Stem Cells Engineering Co., Ltd.1
  • The First Affiliated Hospital with Nanjing Medical University1

Top Investigators

  • Tao Yang1

    The First Affiliated Hospital with Nanjing Medical University

  • Xuqin Zheng1

    The First Affiliated Hospital with Nanjing Medical University

Related Conditions

  • Local Injection1
  • Human Cord Bloodderived Mononuclear Cells1
  • Safety1
  • Efficacy1

Activity Timeline